Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Operations (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash from Operations for 4 consecutive years, with 2480298.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 45.11% to 2480298.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 8446440.0, a 17.25% decrease, with the full-year FY2024 number at 7264795.0, down 20.32% from a year prior.
  • Cash from Operations was 2480298.0 for Q3 2025 at bioAffinity Technologies, up from 2647206.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 376141.0 in Q2 2022 to a low of 2647206.0 in Q2 2025.
  • A 4-year average of 1609515.0 and a median of 1616303.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 261.55% in 2023, then skyrocketed 30.02% in 2025.
  • bioAffinity Technologies' Cash from Operations stood at 1300636.0 in 2022, then dropped by 24.27% to 1616303.0 in 2023, then fell by 3.77% to 1677161.0 in 2024, then plummeted by 47.89% to 2480298.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Cash from Operations are 2480298.0 (Q3 2025), 2647206.0 (Q2 2025), and 1641775.0 (Q1 2025).